Human Vaccines & Immunotherapeutics (Jan 2022)

Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge

  • J. Hoes,
  • H. Pasmans,
  • T. M. Schurink-van ’t Klooster,
  • F. R. M. van der Klis,
  • R. Donken,
  • J. Berkhof,
  • H. E. de Melker

DOI
https://doi.org/10.1080/21645515.2021.1908059
Journal volume & issue
Vol. 18, no. 1

Abstract

Read online

The licensed HPV vaccines are highly efficacious and induce high levels of neutralizing antibody levels, the assumed mediators of protection. However, a correlate of protection against HPV is lacking, and the evidence is still limited as to long-term persistence of antibodies, especially following reduced dosing schedules. The World Health Organization (WHO) urges immunization of young girls as part of the strategy to eliminate cervical cancer, thus long-lasting protection is required. The current review describes long-term follow-up regarding vaccine-induced seropositivity and antibody level development following the different vaccines and dosing schedules. Implications and opportunities of long-term vaccine-induced immune responses are discussed, such as the gaps in monitoring of long-term immunogenicity, the possibilities of reduced dosing schedules, and the importance of evidence for durable immunity.

Keywords